Evidence & concentration worksheet · Growth Hormone & Performance
Ipamorelin 10 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
Ipamorelin is a synthetic five-amino-acid growth hormone secretagogue and ghrelin-receptor agonist. FDA treats ipamorelin free base and ipamorelin acetate as distinct bulk substances and found that the nominations did not consistently identify which one was intended.[1] The National Cancer Institute describes its receptor-level pharmacology but does not identify an approved treatment use.[2]
Benefits & side effects
The largest cited clinical study tested intravenous ipamorelin for postoperative ileus in 117 bowel-resection patients. The difference in time to first tolerated meal was not statistically significant.[5] FDA concluded that effectiveness evidence for growth hormone deficiency or postoperative ileus was limited by any route and that no effectiveness data supported the proposed subcutaneous route.[1]
Online claims about fat loss, muscle gain, anti-aging, sleep, and recovery were not established in ipamorelin-specific controlled human outcome trials reviewed by FDA.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — FDA evaluation of ipamorelin-related bulk drug substances (2024)
- National Cancer Institute — Ipamorelin drug-dictionary entry (2026)
- European Journal of Endocrinology — Ipamorelin, the first selective growth hormone secretagogue (1998)
- Pharmaceutical Research — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy volunteers (1999)
- International Journal of Colorectal Disease — Randomized trial of intravenous ipamorelin for postoperative ileus (2014)
- U.S. FDA — Bulk substances that may present significant compounding safety risks (2026)
- World Anti-Doping Agency — 2026 Prohibited List (2026)
Other vial sizes